In each of these models, 25 tumor‐bearing mice were randomly divided into 5 groups and treated every three days for three weeks with PBS, bare Au nanoparticles, the Au‐AR pep‐PROTAC drug, Au‐Peptide Control, or enzalutamide at the same dose (2 mg kg−1). This evidence concerns the gene AR and neoplasm.